Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “kidney disease: improving Global outcomes” (KDIGO) Controversies conference.
Kidney Int. 2017; 91: 539-551
Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Pediatr Transpl. 2015; 19: E130-E134
Defective complement inhibitory function predisposes to renal disease.
Annu Rev Med. 2013; 64: 307-324
Complement dysregulation and disease: insights from contemporary genetics.
Annu Rev Pathol. 2017; 12: 25-52
Genetics of atypical hemolytic uremic syndrome (aHUS).
Semin Thromb Hemost. 2014; 40: 422-430
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
J Am Soc Nephrol. 2010; 21: 2180-2187
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.
Am J Transplant. 2013; 13: 663-675
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Clin J Am Soc Nephrol. 2010; 5: 1844-1859
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
Clin J Am Soc Nephrol. 2006; 1: 88-99
Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations.
World J Nephrol. 2013; 2: 56-76
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.
Nat Genet. 2013; 45: 531-536
Atypical hemolytic-uremic syndrome.
N Engl J Med. 2009; 361: 1676-1687
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013; 368: 2169-2181
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Curr Opin Nephrol Hypertens. 2013; 22: 704-712
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.
J Am Soc Nephrol. 2010; 21: 859-867
Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.
Clin J Am Soc Nephrol. 2007; 2: 591-596
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genet Med. 2015; 17: 405-424
Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome.
Kidney Int. 2012; 81: 11-13
A multimodality approach to assessing factor I genetic variants in atypical hemolytic uremic syndrome.
Kidney Int Rep. 2019; 4: 1007-1017
The UNOS scientific renal transplant Registry.
Clin Transpl. 1999; : 1-21
Complement alternative pathway deficiency in recipients protects kidney allograft from ischemia/reperfusion injury and alloreactive T cell response.
Am J Transpl. 2017; 17: 2312-2325
Targeting complement pathways during cold ischemia and reperfusion prevents delayed graft function.
Am J Transpl. 2016; 16: 2589-2597
Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).
Immunobiology. 2016; 221: 715-718
High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine.
MMWR Morb Mortal Wkly Rep. 2017; 66: 734-737
Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series.
Am J Kidney Dis. 2017; 70: 770-777
Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.
Am J Transpl. 2010; 10: 168-172
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Nat Rev Nephrol. 2012; 8: 643-657
Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Transplantation. 2014; 98: 1205-1212
Successful prophylactic use of eculizumab in aHUS kidney transplant patients: a report of 9 cases.
Am J Transpl. 2016; 16
Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence.
Transplantation. 2017; 101: 2924-2930
Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome.
Kidney Int Rep. 2019; 4: 434-446
Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome.
J Am Soc Nephrol. 2005; 16: 555-563
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.
Lancet. 2002; 359: 1671-1672
New insights into postrenal transplant hemolytic uremic syndrome.
Nat Rev Nephrol. 2011; 7: 23-35
Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.
Am J Transpl. 2007; 7: 2047-2051
Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.
Transpl Rev (Orlando). 2013; 27: 117-125
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.
Front Med (Lausanne). 2014; 1: 52https://doi.org/10.3389/fmed.2014.00052
Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.
Nephrology (Carlton). 2014; 19: 22-26
Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies.
Clin J Am Soc Nephrol. 2011; 6: 395-403
Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.
Transpl Int. 2015; 28: 1121-1125
Viral-associated thrombotic microangiopathies.
Hematol Oncol Stem Cell Ther. 2011; 4: 51-59
Cyclosporine induces endothelial cell release of complement-activating microparticles.
J Am Soc Nephrol. 2013; 24: 1849-1862
Soliris (eculizumab). Highlights of Prescribing Information. https://alexion.com/Documents/Soliris_USPI.pdf. Updated June 2019. Accessed May 22, 2020.
Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report.
Transpl Proc. 2017; 49: 188-192
De novo thrombotic microangiopathy after kidney transplantation.
Transpl Rev (Orlando). 2018; 32: 58-68
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.
Am J Transpl. 2008; 8: 1694-1701
Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.
Am J Transpl. 2012; 12: 1632-1636